
BIOLOGY

9700/23

Paper 2 AS Level Structured Questions

October/November 2019

MARK SCHEME

Maximum Mark: 60

Published

This mark scheme is published as an aid to teachers and candidates, to indicate the requirements of the examination. It shows the basis on which Examiners were instructed to award marks. It does not indicate the details of the discussions that took place at an Examiners' meeting before marking began, which would have considered the acceptability of alternative answers.

Mark schemes should be read in conjunction with the question paper and the Principal Examiner Report for Teachers.

Cambridge International will not enter into discussions about these mark schemes.

Cambridge International is publishing the mark schemes for the October/November 2019 series for most Cambridge IGCSE™, Cambridge International A and AS Level components and some Cambridge O Level components.

This document consists of **18** printed pages.

PUBLISHED**Generic Marking Principles**

These general marking principles must be applied by all examiners when marking candidate answers. They should be applied alongside the specific content of the mark scheme or generic level descriptors for a question. Each question paper and mark scheme will also comply with these marking principles.

GENERIC MARKING PRINCIPLE 1:

Marks must be awarded in line with:

- the specific content of the mark scheme or the generic level descriptors for the question
- the specific skills defined in the mark scheme or in the generic level descriptors for the question
- the standard of response required by a candidate as exemplified by the standardisation scripts.

GENERIC MARKING PRINCIPLE 2:

Marks awarded are always **whole marks** (not half marks, or other fractions).

GENERIC MARKING PRINCIPLE 3:

Marks must be awarded **positively**:

- marks are awarded for correct/valid answers, as defined in the mark scheme. However, credit is given for valid answers which go beyond the scope of the syllabus and mark scheme, referring to your Team Leader as appropriate
- marks are awarded when candidates clearly demonstrate what they know and can do
- marks are not deducted for errors
- marks are not deducted for omissions
- answers should only be judged on the quality of spelling, punctuation and grammar when these features are specifically assessed by the question as indicated by the mark scheme. The meaning, however, should be unambiguous.

GENERIC MARKING PRINCIPLE 4:

Rules must be applied consistently e.g. in situations where candidates have not followed instructions or in the application of generic level descriptors.

GENERIC MARKING PRINCIPLE 5:

Marks should be awarded using the full range of marks defined in the mark scheme for the question (however; the use of the full mark range may be limited according to the quality of the candidate responses seen).

GENERIC MARKING PRINCIPLE 6:

Marks awarded are based solely on the requirements as defined in the mark scheme. Marks should not be awarded with grade thresholds or grade descriptors in mind.

Mark scheme abbreviations

| | |
|-------------------------|---|
| ; | separates marking points |
| / | alternative answers for the same point |
| R | reject |
| A | accept (for answers correctly cued by the question, or by extra guidance) |
| AW | alternative wording (where responses vary more than usual) |
| <u>underline</u> | actual word given must be used by candidate (grammatical variants accepted) |
| max | indicates the maximum number of marks that can be given |
| ora | or reverse argument |
| mp | marking point (with relevant number) |
| ecf | error carried forward |
| I | ignore |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 1(a)(i) | haem ; A heme / prosthetic group I iron / iron ion / Fe / Fe ²⁺ I porphyrin ring | 1 |
| 1(a)(ii) | <i>one from</i> combines with / binds / carries / transports / AW, oxygen (in lungs) ; R forms bonds releases / AW, oxygen, in tissues / at low oxygen concentrations ; allows haemoglobin to transport oxygen ; | 1 |
| 1(b) | <i>two from</i> 1 spherical / ball-like / rounded / AW ; R circular / round ignore 3D shape 2 (water) soluble / forms H bonds with water ; 3 hydrophilic R-groups on outside of molecule / hydrophobic R-groups on inside ; R ref. to 'tails' 4 dynamic / metabolic / physiological / AW, function ; | 2 |
| 1(c) | made of <u>amino acids</u> ; <i>one from</i> joined by peptide bonds ; R 'peptide bond between two amino acids' R 'dipeptide bond(s)' macromolecule / long-chain (molecule) / large molecule ; repeated / many, (sub-)units / monomers ; | 2 |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 1(d) | <p><i>three from</i></p> <p>1 (R-group of) glutamic acid / glu, is polar / hydrophilic and (R-group of) valine / val, is non-polar / hydrophobic ;</p> <p>2 change in tertiary structure ; A 'change in globular shape / less globular in shape'</p> <p>3 change in quaternary structure of haemoglobin ; R of β-globin</p> <p>4 <i>ref. to</i> haemoglobin forms fibres (with other Hb) ; A 'sticky molecules'</p> <p>5 haemoglobin is less (water) soluble ; I insoluble</p> <p>6 haemoglobin is less efficient at, binding / transporting, oxygen ; A less oxyhaemoglobin A haemoglobin / β-globin, has lower affinity for oxygen A reduced oxygen carrying capacity I haemoglobin, does not / cannot, bind oxygen</p> <p>7 AVP ;</p> | 3 |

PUBLISHED

| Question | Answer | Marks |
|----------|---|----------|
| 1(e) | <p><i>three from</i></p> <p>1 haemoglobin combines with carbon dioxide ;</p> <p>2 carbon dioxide reacts with (terminal), amine group(s) / $-NH_2$ / $-NH$;</p> <p>3 to form <u>carbaminohaemoglobin</u> ; R carboxyhaemoglobin / carbonylhaemoglobin</p> <p>4 each polypeptide can carry a molecule of carbon dioxide / haemoglobin can carry four molecules of carbon dioxide ;</p> <p>5 carbon dioxide remains, bound / AW, to Hb until in, region of low pCO_2 or high pO_2 / pulmonary circulation / lungs / alveoli ;</p> <p>6 <i>ref. to</i> (carbonic acid dissociates to form) hydrogen ions, which bind to / AW, haemoglobin ; A H^+ forms haemoglobinic acid or HHb I hydrogen unqualified</p> <p>7 AVP ; e.g. hydrogencarbonate ions to plasma</p> | 3 |

PUBLISHED

| Question | Answer | Marks | | | | | | | | | | | | |
|------------|--|-------|------------------------------|------------|-------|----------|---|-----------|---|----------|-----------|-----------|-------------------------------------|---|
| 2(a) | <table border="1" data-bbox="456 212 1247 639"> <thead> <tr> <th data-bbox="456 212 736 276">name</th> <th data-bbox="736 212 1247 276">one example of cell from 2.1</th> </tr> </thead> <tbody> <tr> <td data-bbox="456 276 736 339">interphase</td> <td data-bbox="736 276 1247 339">B / G</td> </tr> <tr> <td data-bbox="456 339 736 403">prophase</td> <td data-bbox="736 339 1247 403">A</td> </tr> <tr> <td data-bbox="456 403 736 467">metaphase</td> <td data-bbox="736 403 1247 467">D</td> </tr> <tr> <td data-bbox="456 467 736 531">anaphase</td> <td data-bbox="736 467 1247 531">E / F / C</td> </tr> <tr> <td data-bbox="456 531 736 639">telophase</td> <td data-bbox="736 531 1247 639">C / H R C if stated for anaphase</td> </tr> </tbody> </table> <p data-bbox="349 676 748 772">all five correct = 3 marks three or four correct = 2 marks one or two correct = 1 mark</p> | name | one example of cell from 2.1 | interphase | B / G | prophase | A | metaphase | D | anaphase | E / F / C | telophase | C / H R C if stated for anaphase | 3 |
| name | one example of cell from 2.1 | | | | | | | | | | | | | |
| interphase | B / G | | | | | | | | | | | | | |
| prophase | A | | | | | | | | | | | | | |
| metaphase | D | | | | | | | | | | | | | |
| anaphase | E / F / C | | | | | | | | | | | | | |
| telophase | C / H R C if stated for anaphase | | | | | | | | | | | | | |
| 2(b) | (29 as a percentage of 5000 =) 0.58 (%) ; A 0.6 (%) (0.0058 × 720 minutes =) 4 (min) / 4.2 / 4.18 / 4.176 ; <i>allow ecf</i> | 2 | | | | | | | | | | | | |
| 2(c) | <p data-bbox="349 882 577 946"><i>mark first answer one from</i></p> <ol data-bbox="349 983 1267 1422" style="list-style-type: none"> 1 cell plate forms (across equator of cell) ; 2 cell wall / cellulose, laid down ; A cell wall forms (between the two) 3 <u>cytoplasm</u> divided (into two) ; R cytoplasm, constricts / pinches in I 'separates into two daughter cells' I events at late telophase 4 <i>idea that</i> organelles shared out ; 5 AVP ; detail of cell plate formation e.g. <i>ref. to</i> vesicles transported to equator / involvement of cytoskeletal structures / <i>ref. to</i> phragmoplast | 1 | | | | | | | | | | | | |

PUBLISHED

| Question | Answer | Marks |
|----------|---|----------|
| 3(a) | <p><i>five from</i></p> <p>1 drought-tolerant plants have smaller stomatal aperture and lower, transpiration rate / rate of water uptake ; A ora</p> <p>2 comparative data quote for, mean stomatal aperture / transpiration rate + $\text{mmol m}^{-2} \text{s}^{-1}$ / mean water uptake + cm^3 per shoot + time + h ;</p> <p><i>in drought-tolerant plants</i></p> <p>3 smaller (aperture), stomata so less water (vapour) loss ;</p> <p>4 water vapour <u>diffuses</u> (out) through stomata ;</p> <p>5 less evaporation from (cell walls of) mesophyll ;</p> <p>6 so less <u>transpiration pull</u> ;</p> <p>7 AVP ; suggestion of other adaptations of leaves to reduce water loss e.g. sunken stomata / thicker <u>cuticle</u> / hairs / trichomes / lower <u>stomatal density</u> R closed stomata</p> | 5 |

PUBLISHED

| Question | Answer | Marks |
|-----------------|---|--------------|
| 3(b) | <p>I any ref. to mutation / inhibition of (RNA) polymerase</p> <p>1 microRNA binds to mRNA ; A forms hydrogen bonds with (bases on) mRNA</p> <p>2 bases in microRNA are <u>complementary</u> to bases on mRNA ;</p> <p>3 microRNA makes mRNA too large to leave nuclear pore / mRNA cannot reach ribosomes ;</p> <p>mp4 and mp5 accept alternatives to bind</p> <p>4 mRNA cannot, bind / AW, to (small sub-unit of) ribosome ; A prevents ribosome moving along mRNA</p> <p>5 anticodons of tRNA cannot, bind / AW, to (some) codons on mRNA ;</p> <p>6 no / not all, amino acids are brought to ribosome / AW ;</p> <p>7 AVP ; e.g. complex of microRNA and mRNA recognised for degrading</p> | 3 |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 4(a) | <p><i>artery wall</i></p> <p>I narrow lumen to maintain high (blood) pressure I ref. to valves / ref. to inner lining being wrinkled or wavy</p> <p>1 thick, walled / tunica media, to withstand high (blood) pressure / prevent bursting ;</p> <p>2 endothelium / endothelial cells / tunica intima, are smooth, little friction to blood flow / easy flow of blood / no eddies of blood flow / AW ;</p> <p>3 elastic, tissue / fibres, stretches to allow surges in blood flow / recoils to maintain blood pressure or force blood forward ;</p> <p>4 smooth muscle (contracts to), maintains / regulates / controls blood flow ; A smooth muscle distributes blood</p> <p>5 collagen fibres, avoid rupturing / bursting ;</p> | 4 |
| 4(b)(i) | <p>red blood cells / erythrocytes ; R red and white blood cells</p> <p><i>one from</i> biconcave (shape) ; no nucleus ; <i>idea of</i> uniform, cytoplasm / cell contents ; <i>idea of</i> rouleau / stacked cells ; I 'clumped' I size</p> | 2 |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 4(b)(ii) | <p><i>assuming arteriole unless told otherwise, accept alternative terminology for layers of wall of arteriole</i> I ref. to folding</p> <p>1 thicker wall / more than one layer of cells in wall / has tunica intima, tunica media and tunica adventitia whereas capillary has tunica intima ; A <u>endothelium</u> for tunica intima</p> <p>2 more cells forming, perimeter / tunica intima ;</p> <p>3 wider (vessel) / wider lumen / AW ; A actual width(s)</p> <p>4 nucleus / nuclei, present in wall only in arteriole ;</p> <p>5 cells lining lumen / endothelial cells, are thicker ;</p> <p>6 lumen smaller, relative to the, thickness of the wall / overall width ;</p> <p>7 more (red blood) cells (in lumen) ;</p> <p>8 nuclei projecting inwards only in arteriole ;</p> <p>9 AVP ; e.g. <i>ref. to</i> smooth muscle cells capillaries are surrounded by cells correct calculation of actual sizes using magnifications in Fig. 4.1 arteriole 20–35 μm and capillary 6–7 μm</p> | 4 |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 4(c)(i) | <p>1 higher (hydrostatic) pressure of blood (at start of capillary) ;</p> <p>2 (pressure / ultra) <u>filtration</u> of blood ;</p> <p>3 (causing) leakage / movement out / pushing out, of <u>plasma</u> ; R diffusion</p> <p>4 <i>either</i> glucose / amino acids / salts, (filtered) out <i>or</i> (large) plasma proteins not (filtered) out ;</p> <p>5 AVP ; e.g. <i>ref. to</i> pores / fenestrations / gaps, within / between, endothelial / lining, cells e.g. molecules smaller than MM ~68 000 (g mol^{-1} / daltons) can pass out</p> | 2 |
| 4(c)(ii) | <p>lymph ; A lymphatic (fluid)</p> <p><i>one from</i> I any cells / waste products / toxins / antibodies / fatty acids and glycerol</p> <p>no, named / large / plasma, proteins, e.g. albumen no / little / less, oxygen / glucose higher concentration of / more, carbon dioxide AVP ; e.g. higher concentration of / more, fat / lipids / lipoproteins</p> <p><i>if fluid identified as tissue fluid give one mark as an ECF for a difference between plasma and tissue fluid</i></p> <p>e.g. no, named / large / plasma, proteins e.g. albumen</p> | 2 |

PUBLISHED

| Question | Answer | Marks |
|-----------------|--|--------------|
| 5(a) | <p><i>two from</i></p> <p>protein coat / capsid / capsomeres ;</p> <p>nucleic acid / <u>DNA or RNA</u> (core) ; I single- or double-stranded A 'DNA/RNA' I genetic material</p> <p>size given in nanometres / smaller than prokaryotes ; I small / very small / microscopic I acellular</p> | 2 |
| 5(b) | <p><i>three from</i></p> <p>1 drugs can be <u>inhibitors</u> (of neuraminidase) ;</p> <p><i>either</i></p> <p>2 (competitive inhibitor) so binds to active site <i>or</i> (non-competitive inhibitor) so binds to allosteric site / AW <i>or</i> (drugs may act by) breaking down / hydrolysing / denaturing, all / part of neuraminidase ; A changes active site</p> <p>3 no / less, enzyme-substrate complexes formed ; A ESC A substrate not able to bind to enzyme A neuraminidase cannot bind to (host cell) receptor</p> <p>4 receptor is (still) complementary to haemagglutinin ;</p> <p>5 haemagglutinin becomes attached to, cell receptor / host cell (so newly formed virus does not leave the cells) ;</p> | 3 |

PUBLISHED

| Question | Answer | Marks |
|----------|---|----------|
| 5(c) | <p><i>four from</i></p> <p>1 antigen presentation ; <i>in correct context</i></p> <p>2 clonal selection / activation, of specific, B-lymphocytes / T-lymphocytes ; A B cells / T cells</p> <p>3 (lymphocytes) divide by mitosis / undergo clonal expansion ;</p> <p>4 B-lymphocytes, differentiate into / mature into / form / AW, plasma cells ;</p> <p>5 antibodies secreted by plasma cells ;</p> <p>6 T-helper cells secrete cytokines ;</p> <p>7 cytokines stimulate / AW, B-lymphocytes / plasma cells / humoral response ;</p> | 4 |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 5(d)(i) | <p><i>max 2 (out of total three marks)</i> <i>advantages</i> <i>allow references to other pathogen types</i></p> <p>1 antibodies are provided to people immediately / no delay for plasma cells to secrete antibodies ; A immediate, immunity / protection R immediate (immune) response</p> <p>2 antibodies, immediately neutralise toxins / prevent viruses entering cells ;</p> <p>3 prevents disease (in the individual) / promotes quicker recovery ;</p> <p>4 prevents spread of the pathogen through the population / prevents people dying ;</p> <p>5 antibodies can be manufactured quickly in response to mutations that occur in virus / AW ;</p> <p><i>max 2 (out of total three marks)</i> <i>disadvantages</i></p> <p>6 short-term / temporary (immunity) ;</p> <p>7 no memory cells produced ;</p> <p>8 can have infections of <u>same</u> pathogen again ;</p> <p>9 allergic reaction / immune response, to the (non-human) antibodies given ;</p> <p>10 <i>ref. to cost</i> qualified ; e.g. needs to be repeated / high cost of production of antibodies</p> <p>11 AVP – for advantage (A) or disadvantage (D) ; e.g. (A) passive can be used for people who are malnourished / immunosuppressed e.g. (A) <i>ref. to</i> using a vaccine with a (live) pathogen that might give person the disease</p> | 3 |
| 5(d)(ii) | <p>across the placenta ; A via umbilical cord in breast milk / colostrum / breast feeding / during lactation ;</p> | 2 |

PUBLISHED

| Question | Answer | Marks |
|-----------------|---|--------------|
| 6(a)(i) | nanometres / nm ; | 1 |
| 6(a)(ii) | <p>A ora throughout</p> <p>(presence of) carbohydrate / sugar, chains / residues, on, (glyco)proteins / (glyco)lipids ;</p> <p>A there are no sugar chains on the inner surface A (presence of) glycoproteins / glycolipids (on external surface) A (presence of) cell surface antigens / receptors (on external surface) A (presence of) glycocalyx</p> | 1 |
| 6(b) | <p>R</p> <p>1 cholesterol ;</p> <p><i>one from</i></p> <p>2 maintains / regulates, fluidity of, membrane / phospholipid bilayer <i>or</i> at low temperatures, maintain / increase fluidity / prevents close packing A prevents hydrophobic ‘tails’ interacting at low temperatures <i>or</i> at high temperatures, stabilises the membrane / decreases fluidity ;</p> <p>3 prevents passage (across membrane) of, hydrophilic / polar, substances ;</p> <p>S</p> <p>4 phospholipid (monolayer) ; R phospholipid bilayer</p> | 4 |

PUBLISHED

| Question | Answer | Marks |
|-----------------|--|--------------|
| 6(b) | <p><i>one from</i></p> <p>5 forms a bilayer ;</p> <p>6 (bilayer is a) barrier to, water soluble molecules / polar molecules / ions ; ora not a barrier to lipid soluble molecules / allows lipid soluble molecules to cross membranes A non-polar / AW</p> <p>7 (bilayer is a) non-polar barrier between cytoplasm and (aqueous) surroundings ;</p> <p>8 hydrophilic 'head' forms hydrogen bonds with water ;</p> | |